Message from the Director

Thank you for visiting the website of the Institute for Memory Impairments and Neurological Disorders (UCI MIND).  Your visit indicates a desire to learn more about Alzheimer’s disease or related neurological disorders.   I hope you find this site useful and that it provides the information you are seeking.

Right now, over 5.4 million Americans have Alzheimer’s disease, including over 580,000 individuals in California and 75,000 in Orange County. Even more alarmingly, unless a way is found to delay the onset of Alzheimer’s disease, it is estimated that nearly 14 million people will suffer from this insidious disorder by the year 2050.

Dr. Alois Alzheimer

The Institute is an organized research unit dedicated to investigating the causes of Alzheimer’s disease and related dementias and to improving the quality of life and promoting successful aging. Our vision for the Institute for Memory Impairments and Neurological Disorders is to develop approaches for lessening the impact of memory-related disorders. Tackling these complex issues requires a multi-disciplinary approach, which is reflected in the diversity of our faculty, who have primary appointments in the Schools of Biological Sciences, Computing Sciences, Engineering, Medicine, Nursing Sciences, and Social Sciences.

In my tenure as director of the Institute, I have been most impressed by the dedication and commitment of our faculty and staff. I look forward to working closely with them as we strive for a world without Alzheimer’s disease.


Frank LaFerla, Ph.D.

Chancellor’s Professor of Neurobiology and Behavior

Director, Institute for Memory Impairments and Neurological Disorders

About the Director

  • Dr. Frank LaFerla is the Director of the Institute for Memory Impairments and Neurological Disorders and a Chancellor’s Professor in the Department of Neurobiology and Behavior.
  • Dr. LaFerla earned his Bachelor of Science degree in 1985 from St. Joseph’s University in Philadelphia. He received his training at the University of Minnesota where his dissertation on aspects of efficiency for viral replication earned him his doctorate in 1990.
  • Dr. LaFerla has made significant strides in understanding the molecular development of Alzheimer’s disease. He and his team were the first to create a genetically altered (triple transgenic) mouse that allowed for the concurrent study of the two signature lesions of AD – plaques and tangles. Other research efforts include nicotine studies, beta-amyloid and its relation to the onset of memory decline, and stem cell therapy.
  • For more information about Dr. LaFerla’s research, please visit the LaFerla Lab.